http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2412268-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e5f2d89a8c9d985b85a5d6512df76351 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-912 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2821 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-502 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5091 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate | 2006-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf9d9cb4bef7e7efa09c48a786b9e981 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f3df1debffe25ce907f1a3e4663841a3 |
| publicationDate | 2013-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2412268-T3 |
| titleOfInvention | Alzheimer's disease specific alterations of the ERK1 / ERK2 phosphorylation ratio as specific molecular biomarkers of Alzheimer's Disease (ADSMB) |
| abstract | Method of identifying a leading compound useful for the treatment of Alzheimer's Disease which comprises: a) contacting non-Alzheimer's disease cells with a beta amyloid peptide, in which said non-Alzheimer's Disease cells show absence of Alzheimer's disease because said cells extracted from an individual do not show a measurable or detectable phenotype of Alzheimer's Disease; b) contacting said cells of step (a) with an agent that is an activator of the protein kinase C; c) contacting said cells of step (b) with a test compound; and d) determine the value of a specific molecular biomarker of Alzheimer's Disease to identify a leading compound useful for the treatment of Alzheimer's Disease. wherein the value of said specific molecular biomarker of Alzheimer's Disease is measured by determining the ratio of phosphorylated Erk1 and phosphorylated Erk2 in cells that have been stimulated with a protein kinase C activator and subtracting from it the ratio of phosphorylated Erk1 and Phosphorylated Erk2 in cells that have been stimulated with a control solution lacking protein kinase C activator; and the value of said specific molecular biomarker of Alzheimer's Disease is indicative of a compound useful for the treatment of Alzheimer's Disease if said value is lower than the value of said specific molecular biomarker of Alzheimer's Disease measured in control cells that is not have contacted said test compound. |
| priorityDate | 2005-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 303.